CC-292, A NOVEL BRUTON'S TYROSINE KINASE INHIBITOR ALONE AND IN COMBINATION WITH CARFILZOMIB IMPACTS BONE RESORPTION IN MULTIPLE MYELOMA BY BLOCKING OSTEOCLAST SEALING ZONE FORMATION

被引：0
|
作者：
Eda, H. [1 ]
Loredana, S. [1 ]
Cirstea, D. [1 ]
Yee, A. [1 ]
Mahindra, A. [1 ]
Scullen, T. [1 ]
Nemani, N. [1 ]
Mishima, Y. [1 ]
Kapur, S. [2 ]
Evans, E. [3 ]
Singh, J. [3 ]
Kirke, C. [2 ]
Westlin, W. [3 ]
Raje, N. [1 ]
机构：
[1] Harvard Med Sch, Canc Ctr, MGH, Boston, MA USA
[2] Onyx Pharmaceut Inc, Res Dept, San Francisco, CA USA
[3] Celgene Avil Res, Bedford, England
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S543
引用
收藏
页码：227 / 228
页数：2
相关论文
共 21 条
  • [1] A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity
    Eda, H.
    Santo, L.
    Cirstea, D. D.
    Yee, A. J.
    Scullen, T. A.
    Nemani, N.
    Mishima, Y.
    Waterman, P. R.
    Arastu-Kapur, S.
    Evans, E.
    Singh, J.
    Kirk, C. J.
    Westlin, W. F.
    Raje, N. S.
    LEUKEMIA, 2014, 28 (09) : 1892 - 1901
  • [2] A novel Bruton’s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity
    H Eda
    L Santo
    D D Cirstea
    A J Yee
    T A Scullen
    N Nemani
    Y Mishima
    P R Waterman
    S Arastu-Kapur
    E Evans
    J Singh
    C J Kirk
    W F Westlin
    N S Raje
    Leukemia, 2014, 28 : 1892 - 1901
  • [3] A Novel Bruton's Tyrosine Kinase Inhibitor CC-292 In Combination With The Proteasome Inhibitor Carfilzomib Iimpacts Multiple Myeloma Bone Microenviroment With Resultant Anti-Myeloma Activity
    Eda, Homare
    Santo, Loredana
    Cirstea, Diana D.
    Yee, Andrew J.
    Scullen, Tyler A.
    Nemani, Neeharika
    Mishima, Yuko
    Arastu-Kapur, Shirin
    Evans, Erica
    Singh, Juswinder
    Kirk, Christopher J.
    Westlin, William F.
    Raje, Noopur S.
    BLOOD, 2013, 122 (21)
  • [4] Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton's Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease
    Ziouti, Fani
    Rummler, Maximilian
    Steyn, Beatrice
    Thiele, Tobias
    Seliger, Anne
    Duda, Georg N.
    Bogen, Bjarne
    Willie, Bettina M.
    Jundt, Franziska
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (08)
  • [5] A Chemoproteomics Approach to Determine the Mechanism of Testicular Toxicity for the Bruton's Tyrosine Kinase Inhibitor CC-292
    Labenski, Matt
    Voortman, Lukas
    Medikonda, Aravind Prasad
    Sherratt, Philip J.
    Corin, Alan F.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2021, 379 (02): : 166 - 174
  • [6] Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma
    Eda, Homare
    Santo, Loredana
    Cirstea, Diana D.
    Pozzi, Samantha
    Canavese, Miriam
    Scullen, Tyler A.
    Vallet, Sonia
    Evans, Erica
    Singh, Juswinder
    Raje, Noopur S.
    BLOOD, 2011, 118 (21) : 1243 - 1244
  • [7] A novel Bruton's tyrosine kinase inhibitor, acalabrutinib, suppresses osteoclast differentiation and Porphyromonas gingivalis lipopolysaccharide-induced alveolar bone resorption
    Pokhrel, Nitin Kumar
    Kim, Yong-Gun
    Kim, Hyo Jeong
    Kim, Hyung Joon
    Lee, Ji Hye
    Choi, So-Young
    Kwon, Tae-Geon
    Lee, Heon-Jin
    Kim, Jae-Young
    Lee, Youngkyun
    JOURNAL OF PERIODONTOLOGY, 2019, 90 (05) : 546 - 554
  • [8] Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia
    Brown, Jennifer R.
    Harb, Wael A.
    Hill, Brian T.
    Gabrilove, Janice
    Sharman, Jeff P.
    Schreeder, Marshall T.
    Barr, Paul M.
    Foran, James M.
    Miller, Thomas P.
    Burger, Jan A.
    Kelly, Kevin R.
    Mahadevan, Daruka
    Ma, Shuo
    Li, Yan
    Pierce, Daniel W.
    Barnett, Evelyn
    Marine, Jeffrey
    Miranda, Monika
    Azaryan, Ada
    Yu, Xujie
    Nava-Parada, Pilar
    Mei, Jay
    Kipps, Thomas J.
    HAEMATOLOGICA, 2016, 101 (07) : 295 - 298
  • [9] Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lyrnphocytic Leukemia (CLL)
    Brown, Jennifer R.
    Harb, Wael A.
    Hill, Brian T.
    Gabrilove, Janice
    Sharman, Jeff P.
    Schreeder, Marshall T.
    Barr, Paul M.
    Foran, James M.
    Miller, Thomas P.
    Burger, Jan A.
    Kelly, Kevin R.
    Mahadevan, Daruka
    Ma, Shuo
    Barnett, Evelyn
    Marine, Jeffrey
    Nava-Parada, Pilar
    Azaryan, Ada
    Mei, Jay
    Kipps, Thomas J.
    BLOOD, 2013, 122 (21)
  • [10] PHASE 1 STUDY OF SINGLE AGENT CC-292, A HIGHLY SELECTIVE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Brown, J. R.
    Harb, W. A.
    Hill, B. T.
    Gabrilove, J.
    Sharman, J. P.
    Schreeder, M. T.
    Barr, P. M.
    Foran, J. M.
    Miller, T. P.
    Burger, J. A.
    Kelly, K. R.
    Mahadevan, D.
    Ma, S.
    Barnett, E.
    Marine, J.
    Nava-Parada, P.
    Azaryan, A.
    Mei, J.
    Kipps, T. J.
    HAEMATOLOGICA, 2014, 99 : 54 - 55
123